July 18, 2013

ImmuCell ends search for partner to market Mast Out

ImmuCell had reached out to a variety of large and small animal health companies, but failed to 'establish terms which we consider to be fair and reasonable to both parties.'

By Jessica Hall jhall@pressherald.com
Staff Writer

PORTLAND — ImmuCell Corp. said it suspended its efforts to find a partner for Mast Out, its mastitis treatment product under development for dairy cows, after failing to reach an agreement to commercialize the product.

Shares of ImmuCell fell 14 percent, or 55 cents, to $3.35 in morning trading.

Mastitis is inflammation of breast tissue. 

ImmuCell had reached out to a variety of large and small animal health companies. During the second quarter, ImmuCell had received a $250,000 exclusive option payment from one prospective partner who decided not to pursue a license after its final due diligence, ImmuCell said. 

ImmuCell was informed by the prospective partner that it “… could not cost effectively commercialize the product.” It did not name the potential partner.

During the due diligence and negotiation process, ImmuCell continued to move toward approval by the Center for Veterinary Medicine and U.S. Food and Drug Administration.

“We are encouraged by the feedback from all prospective partners that our novel mastitis treatment can achieve FDA approval and have a significant, positive impact on the dairy industry,” said ImmuCell President and Chief Executive Michael Brigham. “Having been unable to establish terms which we consider to be fair and reasonable to both parties, we have decided to complete the final stages of the FDA approval process on our own in order to realize the optimal value for our stockholders.”

Commercial sales of Mast Out cannot begin until the company's New Animal Drug Application is approved by the FDA. Previously, the FDA confirmed that the regulatory requirements to demonstrate effectiveness and safety had been met, as well as granting Mast Out both “zero milk discard” and “zero meat withhold” claims.

This novel regulatory clearance creates a significant economic benefit to dairy producers by allowing them to sell milk while a cow is being treated.  No other intramammary mastitis treatment can claim this “no-discard” status, ImmuCell said.

Were you interviewed for this story? If so, please fill out our accuracy form

Send question/comment to the editors




Further Discussion

Here at PressHerald.com we value our readers and are committed to growing our community by encouraging you to add to the discussion. To ensure conscientious dialogue we have implemented a strict no-bullying policy. To participate, you must follow our Terms of Use.

Questions about the article? Add them below and we’ll try to answer them or do a follow-up post as soon as we can. Technical problems? Email them to us with an exact description of the problem. Make sure to include:
  • Type of computer or mobile device your are using
  • Exact operating system and browser you are viewing the site on (TIP: You can easily determine your operating system here.)